10 Best Foreign Stocks With Dividends For Passive Income

6. Sanofi (NASDAQ:SNY)

Dividend Yield as of February 3: 3.91%

Number of Hedge Fund Holders: 32

Headquartered in Paris, France, Sanofi (NASDAQ:SNY) is a global healthcare company providing therapeutic solutions for diabetes, cardiovascular diseases, rare diseases, oncology, and immunology, alongside established prescription medicines. In January this year, the company shared that it has partnered with Alloy Therapeutics to create a trailblazing central nervous system drug, deploying Alloy’s AntiClastic Antisense platform. This $427 million deal aims to develop a technology meant to cross the blood-brain barrier and tackle RNA-level targets effectively.

In 2024, Sanofi (NASDAQ:SNY) worked hard to become primarily a biopharma company, which included selling a dominant stake in Opella, a major company in the over-the-counter and vitamins, minerals, and supplements market. SNY also reported robust double-digit sales growth and successful product launches.

Sanofi (NASDAQ:SNY) disclosed a free cash flow of €6 billion in 2024, which was brought down by slashed prices of Lantus in H1 in the US, eliminating receivables, and unfavorable exchange rate impact. The company expects cash flow to rebound in 2025 and 2026. In Q2 2025, Sanofi will also receive billions of euros once the Opella transaction goes through. In 2025, SNY’s share repurchases will reach €5 billion and it will pay €3.92 per share dividend for 2024. Sanofi is a dividend aristocrat, with 30 consecutive years of dividend hikes under its belt, making it one of the best foreign stocks for an income portfolio.

Ken Fisher’s Fisher Asset Management is the leading stakeholder of the company, with 13.35 million shares worth roughly $770 million. Overall, 32 hedge funds were bullish on Sanofi (NASDAQ:SNY) at the end of the third quarter of 2024.